"Cisplatin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An inorganic and water-soluble platinum complex. After undergoing hydrolysis, it reacts with DNA to produce both intra and interstrand crosslinks. These crosslinks appear to impair replication and transcription of DNA. The cytotoxicity of cisplatin correlates with cellular arrest in the G2 phase of the cell cycle.
| Descriptor ID |
D002945
|
| MeSH Number(s) |
D01.210.375 D01.625.125 D01.710.100
|
| Concept/Terms |
Cisplatin- Cisplatin
- cis-Diamminedichloroplatinum(II)
- Platinum Diamminodichloride
- Diamminodichloride, Platinum
- cis-Platinum
- cis Platinum
- Dichlorodiammineplatinum
- cis-Diamminedichloroplatinum
- cis Diamminedichloroplatinum
- cis-Dichlorodiammineplatinum(II)
|
Below are MeSH descriptors whose meaning is more general than "Cisplatin".
Below are MeSH descriptors whose meaning is more specific than "Cisplatin".
This graph shows the total number of publications written about "Cisplatin" by people in this website by year, and whether "Cisplatin" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 1 | 1 |
| 1996 | 1 | 2 | 3 |
| 1997 | 1 | 2 | 3 |
| 1998 | 2 | 3 | 5 |
| 1999 | 1 | 1 | 2 |
| 2000 | 0 | 5 | 5 |
| 2001 | 0 | 4 | 4 |
| 2002 | 1 | 3 | 4 |
| 2003 | 3 | 4 | 7 |
| 2004 | 2 | 3 | 5 |
| 2005 | 0 | 2 | 2 |
| 2006 | 1 | 0 | 1 |
| 2007 | 1 | 7 | 8 |
| 2008 | 6 | 6 | 12 |
| 2009 | 1 | 3 | 4 |
| 2010 | 3 | 6 | 9 |
| 2011 | 3 | 6 | 9 |
| 2012 | 1 | 3 | 4 |
| 2013 | 4 | 4 | 8 |
| 2014 | 3 | 5 | 8 |
| 2015 | 4 | 4 | 8 |
| 2016 | 2 | 1 | 3 |
| 2017 | 2 | 2 | 4 |
| 2018 | 4 | 1 | 5 |
| 2019 | 9 | 2 | 11 |
| 2020 | 0 | 6 | 6 |
| 2021 | 1 | 6 | 7 |
| 2022 | 1 | 3 | 4 |
| 2023 | 1 | 6 | 7 |
| 2024 | 2 | 5 | 7 |
To return to the timeline,
click here.
Below are the most recent publications written about "Cisplatin" by people in Profiles.
-
Phase II Trial of Induction Chemotherapy for Advanced Sinonasal Squamous Cell Carcinoma. Clin Cancer Res. 2025 Jan 17; 31(2):258-265.
-
SWOG S1815: A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers. J Clin Oncol. 2025 Feb 10; 43(5):536-544.
-
Polyploid cancer cells reveal signatures of chemotherapy resistance. Oncogene. 2025 Mar; 44(7):439-449.
-
DNA Damage Response Alterations Predict for Neoadjuvant Chemotherapy Sensitivity in Muscle-Invasive Bladder Cancer: A Correlative Analysis of the SWOG S1314 Trial. JCO Precis Oncol. 2024 Nov; 8:e2400287.
-
The Effects of Metformin on Cisplatin-Induced Ototoxicity in Diabetic Patients. Otolaryngol Head Neck Surg. 2025 Jan; 172(1):243-253.
-
Targeted Dynamic Phospho-Proteogenomic Analysis of Gastric Cancer Cells Suggests Host Immunity Provides Survival Benefit. Mol Cell Proteomics. 2024 Dec; 23(12):100870.
-
Doxorubicin, Paclitaxel, and Cisplatin (ATP) for Relapsed/Refractory Germ Cell Tumors. Clin Genitourin Cancer. 2024 Dec; 22(6):102242.
-
The cochlear dose and the age at radiotherapy predict severe hearing loss after passive scattering proton therapy and cisplatin in children with medulloblastoma. Neuro Oncol. 2024 Oct 03; 26(10):1912-1920.
-
Results of a randomized phase II trial of paclitaxel and carboplatin versus bleomycin, etoposide and cisplatin for newly diagnosed and recurrent Chemonaive stromal ovarian tumors: An NRG oncology/gynecologic oncology group study14. Gynecol Oncol. 2024 Nov; 190:283-290.
-
A Phase I Open-Label Study of Cediranib Plus Etoposide and Cisplatin as First-Line Therapy for Patients With Extensive-Stage Small-Cell Lung Cancer or Metastatic Neuroendocrine Non-Small-Cell Lung Cancer. Clin Lung Cancer. 2024 Nov; 25(7):601-611.